190 related articles for article (PubMed ID: 24692686)
1. New treatment paradigm for patients with anaplastic oligodendroglial tumors.
Polivka J; Polivka J; Rohan V; Topolcan O
Anticancer Res; 2014 Apr; 34(4):1587-94. PubMed ID: 24692686
[TBL] [Abstract][Full Text] [Related]
2. Low-grade and anaplastic oligodendroglioma.
Van Den Bent MJ; Bromberg JE; Buckner J
Handb Clin Neurol; 2016; 134():361-80. PubMed ID: 26948366
[TBL] [Abstract][Full Text] [Related]
3. Chromosome 1p/19q status combined with expression of p53 protein improves the diagnostic and prognostic evaluation of oligodendrogliomas.
Xiong J; Liu Y; Wang Y; Ke RH; Mao Y; Ye ZR
Chin Med J (Engl); 2010 Dec; 123(24):3566-73. PubMed ID: 22166632
[TBL] [Abstract][Full Text] [Related]
4. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
[TBL] [Abstract][Full Text] [Related]
5. Co-deletion of 1p/19q as Prognostic and Predictive Biomarker for Patients in West Bohemia with Anaplastic Oligodendroglioma.
Polivka J; Polivka J; Repik T; Rohan V; Hes O; Topolcan O
Anticancer Res; 2016 Jan; 36(1):471-6. PubMed ID: 26722084
[TBL] [Abstract][Full Text] [Related]
6. Anaplastic oligodendroglioma: a new treatment paradigm and current controversies.
Roth P; Wick W; Weller M
Curr Treat Options Oncol; 2013 Dec; 14(4):505-13. PubMed ID: 23907441
[TBL] [Abstract][Full Text] [Related]
7. Treatment of anaplastic glioma.
Wick W; Wiestler B; Platten M
Cancer Treat Res; 2015; 163():89-101. PubMed ID: 25468227
[TBL] [Abstract][Full Text] [Related]
8. How to use molecular markers when caring for a patient with brain cancer: 1P/19Q as a predictive and prognostic marker in the neuro-oncology clinic.
van den Bent MJ
Am Soc Clin Oncol Educ Book; 2013; ():114-6. PubMed ID: 23714473
[TBL] [Abstract][Full Text] [Related]
9. Success at last: a molecular factor that informs treatment.
Lassman AB
Curr Oncol Rep; 2013 Feb; 15(1):47-55. PubMed ID: 23247800
[TBL] [Abstract][Full Text] [Related]
10. Gliomas with 1p/19q codeletion: a.k.a. oligodendroglioma.
Cairncross G; Jenkins R
Cancer J; 2008; 14(6):352-7. PubMed ID: 19060598
[TBL] [Abstract][Full Text] [Related]
11. Oligodendrogliomas: clinical significance of 1p and 19q chromosomal deletions.
Sonabend AM; Lesniak MS
Expert Rev Neurother; 2005 Nov; 5(6 Suppl):S25-32. PubMed ID: 16274268
[TBL] [Abstract][Full Text] [Related]
12. Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features.
van den Bent MJ; Looijenga LH; Langenberg K; Dinjens W; Graveland W; Uytdewilligen L; Sillevis Smitt PA; Jenkins RB; Kros JM
Cancer; 2003 Mar; 97(5):1276-84. PubMed ID: 12599236
[TBL] [Abstract][Full Text] [Related]
13. Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas.
Bauman GS; Ino Y; Ueki K; Zlatescu MC; Fisher BJ; Macdonald DR; Stitt L; Louis DN; Cairncross JG
Int J Radiat Oncol Biol Phys; 2000 Oct; 48(3):825-30. PubMed ID: 11020580
[TBL] [Abstract][Full Text] [Related]
14. Pilot evaluation of 1p and 19q deletions in anaplastic oligodendrogliomas collected by a national cooperative cancer treatment group.
Jenkins RB; Curran W; Scott CB; Cairncross G
Am J Clin Oncol; 2001 Oct; 24(5):506-8. PubMed ID: 11586105
[TBL] [Abstract][Full Text] [Related]
15. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine.
Stege EM; Kros JM; de Bruin HG; Enting RH; van Heuvel I; Looijenga LH; van der Rijt CD; Smitt PA; van den Bent MJ
Cancer; 2005 Feb; 103(4):802-9. PubMed ID: 15637687
[TBL] [Abstract][Full Text] [Related]
16. Anaplastic oligodendroglial tumors harboring 1p/19q deletion can be successfully treated without radiotherapy.
Iwadate Y; Matsutani T; Shinozaki N; Saeki N
Anticancer Res; 2011 Dec; 31(12):4475-9. PubMed ID: 22199318
[TBL] [Abstract][Full Text] [Related]
17. Anaplastic glioma: current treatment and management.
Le Rhun E; Taillibert S; Chamberlain MC
Expert Rev Neurother; 2015 Jun; 15(6):601-20. PubMed ID: 25936680
[TBL] [Abstract][Full Text] [Related]
18. Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker?
Weller M; Berger H; Hartmann C; Schramm J; Westphal M; Simon M; Goldbrunner R; Krex D; Steinbach JP; Ostertag CB; Loeffler M; Pietsch T; von Deimling A;
Clin Cancer Res; 2007 Dec; 13(23):6933-7. PubMed ID: 18056167
[TBL] [Abstract][Full Text] [Related]
19. Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors.
Ueki K; Nishikawa R; Nakazato Y; Hirose T; Hirato J; Funada N; Fujimaki T; Hojo S; Kubo O; Ide T; Usui M; Ochiai C; Ito S; Takahashi H; Mukasa A; Asai A; Kirino T
Clin Cancer Res; 2002 Jan; 8(1):196-201. PubMed ID: 11801559
[TBL] [Abstract][Full Text] [Related]
20. Correlation between genetic alteration and long-term clinical outcome of patients with oligodendroglial tumors, with identification of a consistent region of deletion on chromosome arm 1p.
Hashimoto N; Murakami M; Takahashi Y; Fujimoto M; Inazawa J; Mineura K
Cancer; 2003 May; 97(9):2254-61. PubMed ID: 12712480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
